Peripheral Drug-Eluting Stents Market Size, Share and Global Trend By Type (Self-Expanding, Balloon Expanding), By Indication (Atherosclerosis, Deep Vein Thrombosis), By End User (Clinics, Hospitals, Ambulatory Surgery Centres), and Regional Forecast, 2024-2032

A peripheral drug-eluting stent is a type of endovascular intervention device which is widely used for the treatment of peripheral artery disease. Drug-eluting stents release drugs into arteries which prevents narrowing of arteries as well as cell proliferation. Peripheral artery disease is caused due to the saturation of fats in arteries which are responsible for irregular blood flow to vital organs. Certain factors such as tobacco consumption, smoking, diabetes, obesity, high cholesterol, and high blood pressure are responsible for peripheral artery disease. Untreated peripheral artery disease may lead to conditions such as critical limb ischemia as well as brain damage. According to the American Heart Association, an estimated 40.0% of the adult population in the U.S. translating into 94.6 million people were suffering from high cholesterol in 2017. 

Increasing tobacco consumption, rising prevalence of hypertension and growth in obesity are leading to the increasing prevalence of peripheral artery disease, which represents a higher opportunity for increased demand for global peripheral drug-eluting stents market during the forecast period. According to the American Heart Association, in 2017, 6.8 million people above 40 years were suffering from peripheral artery disease in the U.S. alone. Also, certain benefits of peripheral drug-eluting stents over other endovascular intervention such as prevention of plaque build-up, reduction in recovery time and improved blood circulation are expected to boost the adoption of peripheral drug-eluting stents during the forecast period of 2019-2026. 

However, adverse effects of an allergic reaction due to stent material, high cost of the stents and increased risk of infection are restraining factors for the growth of global peripheral drug-eluting stents market.  

Key Players Covered 

Some of the major companies that are present in the global peripheral drug-eluting stents market are Meril Life Sciences Pvt. Ltd., vascular SLU, Cook, W. L. Gore & Associates, Abbott, STENTYS SA, B. Braun Melsungen AG, Boston Scientific Corporation, and others. 

SEGMENTATION 

In 2018, hospitals dominated the global peripheral drug-eluting stents market due to the rise in a number of patients admitted a higher demand for drug-eluting stents for peripheral artery diseases.  The segment is projected to continue its dominance its market share during the forecast period. 

Key Insights 

• PESTEL analysis
• Prevalence of Peripheral Artery Diseases, By Key Regions
• Pricing Analysis of Key Players in Major Countries/Regions
• Technological Advancements
• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions 

Regional Analysis 

North America dominated the global peripheral drug-eluting stents market in 2018 owing to rise in the prevalence of peripheral artery diseases, leading to higher demand and adoption for drug-eluting stunts and also rise in per capita expenditure resulting. Rapidly increasing obese and diabetic population, a rise in the incidence of blood pressure and high cholesterol has led to rising in the prevalence of peripheral artery disease. According to Institute for Health Metrics and Evaluation, amongst the total number of global obese population, 13.0% population is residing in the U.S. Combined with these factors, well-developed healthcare infrastructure and recent advancements in minimally invasive techniques are responsible for higher adoption of peripheral drug-eluting stents. Europe and the Asia Pacific are expected to grow at a significant CAGR during the forecast period of 2019-2026. 

Key Industry Developments     

• In September 2018, Boston Scientific Corporation received U.S. Food and Drug Administration (FDA) approval for Eluvia Drug-Eluting Vascular Stent System, specifically developed for the treatment of peripheral artery disease (PAD).
• In September 2018, Cook received U.S. Food and Drug Administration (FDA) approval for the new 5 mm diameter version of Zilver PTX. The Zilver PTX was first launched in 2014, was said to be Canada's first drug-coated stent for the treatment of peripheral arterial disease (PAD) in the superficial femoral artery.